Medela, Inc. Receives Wound Care Education Institute, Inc.® Certification

MCHENRY, Ill., June 30, 2015/PRNewswire/ – Medela, Inc., has banded together with the Wound Care Education Institute, Inc.® (WCEI), the nation’s driving wound consideration training supplier, to give industry affirmation to Medela’s expert wound consideration staff. The main of its kind, the Certified Wound Care Market Specialist (CWCMS®) system was made to teach proficient groups on proof based current measures of consideration in wound administration. WCEI has effectively prepared and confirmed about 1,000 wound consideration deals and promoting experts in both medicinal services and assembling commercial ventures.

“Medela Healthcare has given Negative Pressure Wound Therapy since 2008 through our accomplished group and PartnerFirst™ Network,” said Alan Cawley, Director of Sales for Medela Healthcare. “This WCEI affirmation backings Medela’s dedication to giving our clients, and at last the patients we accomplice to serve, with unparalleled mastery.”

“This association guarantees Medela deals and advertising faculty keep on having the right stuff and competency in the developing field of wound consideration to bolster clinicians across the nation,” said Nancy Morgan, president and prime supporter of Wound Care Education Institute, Inc. “This sort of exceptionally centered preparing in wound consideration speaks to a developing chance to enhance the general clinical results for wound consideration patients.”

About Medela The Medela family organization, headquartered in the Canton of Zug, Switzerland, was established by Olle Larsson in 1961. Medela focuses on two specialties units: “Breastfeeding,” with essential research that is perceived internationally and driving in the improvement and assembling of breastfeeding items, and “Healthcare,”engineering and assembling very imaginative therapeutic vacuum innovation arrangements. Medela has 18 auxiliaries in Europe, North America and Asia, circulates its items in more than 90 nations, and utilizes more than 1,500 staff around the world. For more data, visit

Negative pressure wound therapy pumps from Medela, KCI, and Smith and Nephew are no available for reasonable price.

About the WCEI Founded in 2003 by Nancy Morgan RN, BSN, MBA, WOC, WCC, CWCMS, DWC, OMS and Donna Sardina RN, MHA, WCC, CWCMS, DWC, OMS, Wound Care Education Institute, Inc. has developed to turn into the main instructive middle of greatness for wound consideration and ostomy instruction in the United States. WCEI’s central goal is to create multi-disciplinary wound consideration experts by offering preparing projects in light of momentum benchmarks of consideration and confirmation based exploration. To date, WCEI has prepared more than 25,000 wound consideration doctors, advisors, medical attendants and deals/advertising experts. For data in regards to WCEI’s instructive projects, visit www.wcei.

House Votes to Repeal 2.3% ACA Medical Device Tax

The Affordable Care Act may have survived one of its greatest difficulties a week ago with a good controlling from the Supreme Court on King v. Burwell, however one of its less famous procurements may tumble to the administrative process. A bill requiring the cancelation of a questionable 2.3 percent therapeutic gadget assessment has passed a vote in the House and now heads to the Senate, leaving medicinal gadget makers on the edge of their seats as they hold up to perceive how Congress will address the issue.

The extract expense went live toward the start of 2013, squeezing a little more than two percent of the producer’s expressed costs from specific classes of managed therapeutic gadgets, including substitution joints, pacemakers, and other implantable gadgets, some of which are turning out to be progressively essential for remote patient checking and human services’ Internet of Things.

The FDA has attempted to calm the apprehensions of numerous wellbeing IT organizations by saying that it doesn’t expect to place buyer grade mHealth gadgets, quiet engagement applications, or generally safe restorative reconnaissance devices on the rundown of assessable gadgets. Applications and hardware that oversee wellbeing data or medicinal information won’t be entirely controlled either, said FDA authorities recently.

“The FDA tries to propel general wellbeing by advancing advancement and improvement around there by persistently adjusting our administrative way to deal with mechanical advances to address the issues of patients and buyers,” the organization said in a February blog entry. “The restorative gadget information frameworks (MDDS) direction affirms our goal to not implement agreeability with appropriate regulations for innovations that get, transmit, store, or showcase information from therapeutic gadgets. We trust that finish of this strategy will make a force for the advancement of new innovations to better utilize and presentation this information.”

Still, therapeutic gadget producers that are liable to the extract expense have brought up issues of its potential effect on their capacity to develop and flourish in an exceedingly focused commercial center. Elected authorities have anticipated that the duty will bring $29 billion up in income for the administration, a noteworthy aggregate for designers who put in quite a long while toward the start of the decade pondering when the FDA was going to draw up the principles for the mHealth business, which had begun encountering quick development and mind boggling interest.

The medicinal gadget assessment repeal, HR 160, passed a House vote 280 to 140, drawing in “yes” votes from both sides. Notwithstanding the effective edge, it confronts an indeterminate political future in the Senate. Regardless of the possibility that it clears its second Congressional obstacle, President Obama has debilitated to veto the nullification.

Advocates of the assessment say that it will keep on creating quite required income without essentially affecting the exercises of producers. Supporters of cancelation note that the extract has officially gathered far not exactly foreseen, and the lost income is keeping medicinal gadget producers from putting resources into greatly required development, incorporating extending openings for work in their home areas.

A 2014 report from the Congressional Research Service anticipated that the restorative gadget duty would do little to effect makers. “The evaluations in this report propose genuinely minor impacts, with yield and job in the business falling by close to two-tenths of one percent,” the brief expressed. “This restricted impact is because of the little duty rate, the exception of more or less a large portion of yield, and the generally obtuse interest for wellbeing administrations.”

“The investigation recommends that a large portion of the assessment will fall on purchaser costs, and not on benefits of restorative gadget organizations. The impact on the cost of human services, in any case, will no doubt be unimportant in view of the little size of the duty and little share of social insurance spending owing to therapeutic gadgets.”

Be that as it may, therapeutic gadget makers see it in an unexpected way. As indicated by them, the duty is keeping them from putting resources into their own development, which thusly affects the capacity of the social insurance industry everywhere to proceed with its change into an information driven, investigation minded wellbeing IT continuum that can saddle the colossal capability of consistent restorative gadget incorporation and interoperable wellbeing data administration.

“At the point when the duty went into play, my shareholders still anticipate that me will deliver the same returns as we delivered before,” countered Haemonetics Corporation CEO Brian Concannon to journalists from the Boston Globe. The blood handling gadget maker has surrendered give or take $4 million in income to the expense as such. An identical aggregate would permit him to contract 40 extra specialists. “In the event that that expense goes away, I could burn through a great many dollars all the more on innovative work without so much as a second thought,” he included.

Equinox Medical, LLC. Best negative pressure wound therapy pump system manufacturer in the united states of america. Kinetic and Smith and Nephew carries similar products in their portfolio

As the enactment makes headway, spending plan minded Senators will tussle over how to supplant lost income from the duty, if it be canceled. While the therapeutic gadget extract gathered give or take $1 billion not exactly foreseen amid its first year, the dubious effect of cancelation on the social insurance industry and the government spending plan everywhere will remain a divisive issue as the bill advances through the authoritative procedure.

FDA to Strengthen Definitional Standards for Surgical Gowns Under New Guidance

It is a notorious picture imitated amid each and every irresistible ailment flare-up in the most recent century: men and ladies clad head to toe in surgical outfits and surgical covers, keeping an eye on the wiped out or attempting to clean sullied territories. However, notable or not, the US Food and Drug Administration (FDA) has an additionally squeezing concern: Are the outfits successful at shielding their clients from the spread of disease?


The inquiry is the center of another draft direction record issued by FDA, Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings.

Under 21 CFR 878.4040, surgical attire is characterized as:

“gadgets that are planned to be worn by working room faculty amid surgical methodology to secure both the surgical patient and the working room staff from exchange of microorganisms, body liquids, and particulate material. Cases incorporate surgical tops, hoods, veils, outfits, working room shoes and shoe spreads, and confinement covers and outfits. Surgical suits and dresses, ordinarily known as scour suits, are prohibited.”

Equinox Medical, LLC. Fastest Growing Negative Pressure Wound Therapy pump system manufacturer in the United States Of America.

As FDA clarifies in its new draft direction record, not all surgical defensive hardware is controlled similarly.

Under 21 CFR 878.4040(b)(1), surgical outfits and surgical covers are Class II medicinal gadgets and require the accommodation of a 510(k) application and agreeability with both general and uncommon controls built up by FDA under 21 CFR 878.4040(b).

Light and portable Halo Mini NPWT Pump system is now available to the united state of america. The wound pump has similar functions of any kci wound pumps, and smith and nephew pump system in the wound care market.

Nonetheless, not all surgical attire is managed as Class II gadgets. Except for surgical outfits and veils, most surgical attire is directed as Class I therapeutic gadgets (21 CFR 878.4040(b)(2)). Class I items are absolved from premarket entries or survey, however must consent to general controls built up by FDA.


As FDA has already noticed, the execution of surgical outfits, and specifically surgical confinement outfits, is basic. In the event that you have motivation to wear a surgical outfit in any case, the exact opposite thing you need to stress over is whether fluid splatter containing an irresistible microorganism will leak through and come into contact with your skin.

The issue, as FDA clarifies in the direction, is that definitional perplexity at present exists in the commercial center. Case in point, a few norms setting bodies utilize the expression “disengagement outfit” to portray what FDA calls “surgical outfits.” That’s conceivably dangerous in light of the fact that FDA considers outfits guaranteeing to give more elevated amounts of hindrance security “to be higher-hazard gadgets than those that claim negligible or low levels of boundary assurance.”

In the event that conflicting definitions are utilized, organizations may accept they are excluded from giving the obliged execution proof, FDA said. “The motivation behind this direction, along these lines, is to elucidate and portray the premarket administrative necessities relating to outfits directed under 21 CFR 878.4040 and the execution testing expected to bolster fluid hindrance claims for outfits proposed for utilization in health awareness settings,” FDA included.

The Guidance

FDA’s direction depends upon a current standard kept up by the American National Standards Institute (ANSI) and the Association for the Advancement of Medical Instrumentation (AAMI) known as ANSI/AAMI PB70. The PB70 standard portrayed four levels of security, with Level 1 insurance offering a “negligible” measure of hindrance assurance, and Level 4 offering “high” obstruction security.

FDA says it considers Levels 1 and 2 to on the whole offer “insignificant or low” obstruction security, and Levels 3 and 4 to offer “moderate or high” boundary insurance.

As FDA’s direction archive goes ahead to clarify, the cases made by a maker about its surgical attire (under 21 CFR 878.4040(b)(2)) will decide how it is controlled by FDA.

An outfit (not a surgical outfit) which is named with articulations that it is expected to give insignificant or low obstruction insurance may be directed as a Class I gadget absolved from premarket survey.

In any case, if that same item is named as a surgical outfit, cases to give “moderate or abnormal state obstruction security,” or is proposed for utilization amid sterile systems, it will be managed as a Class II gadget and be liable to the 510(k) procedure and unique controls set up by FDA.

On the off chance that a 510(k) is needed of a surgical outfit or related gadget, FDA says it must meet the PB70 standard and incorporate execution test information planned to exhibit hindrance adequacy.

Under the new approach, existing items as of now available however obliging a 510(k) will be conceded makeshift mercy, FDA said.

Remarks on the direction record are because of FDA before the end of August 2015.

Pioneers Memorial Hospital Uses The Luvo Model of Wound Center Management by Wound Care Advantage

Pioneers Memorial Hospital Uses The Luvo Model of Wound Center Management by Wound Care Advantage

Pioneers Memorial Healthcare District has partnered with Wound Care Advantage (WCA) joining a growing number of hospitals seeking alternative solutions to wound center management.

Pioneers Memorial Healthcare District in Brawley, CA. recently partnered with Wound Care Advantage (WCA) to utilize the Luvo model of management for their outpatient wound center. The partnership strengthens the hospital’s commitment to the specialty of wound care by joining a network of wound centers across the country working with WCA to manage their outpatient wound center.

The Wound Clinic at Pioneers offers advanced wound care treatments and hyperbaric oxygen therapy to help heal wounds – including diabetic wounds of the lower extremities, pressure ulcers, venous stasis ulcers, ischemic ulcers, traumatic ulcers, radiation wounds, atypical wounds and post-surgical wounds.


Poor circulation, infection, diabetes, obesity and injuries can cause advanced wounds that are difficult to heal without specialty care. The relative 5-year mortality rate for diabetics after limb amputation is 68 percent. Wound healing increases patient quality of life and works toward limb preservation in patients both with and without diabetes.

“Offering hyperbaric oxygen therapy locally provides state-of-the-art advanced medicine to treat chronic, non-healing wounds while reducing amputations,” Art Mejia, MPA, FACHE, Associate Administrator Clinics & Support Services Pioneers Memorial Healthcare District said. “These types of conditions can be common in communities such as ours, which struggles with issues such as uncontrolled diabetes. The expansion of our wound clinic means that patients no longer have to travel outside of Imperial County to receive this necessary treatment.”

The wound center is currently utilizing several Luvo modules including Keystone, Prism, Resume, Pressure, Lighthouse and Chalkboard.

“The biggest benefit to using the Luvo operating system is that the system is 100 percent based in wound care patient management,” Mejia said. “All of the functionality that has been developed across the system, from entry to maintenance to reporting, is intended to support the medical practice of wound care. It should prove to be a great resource with which to continuously improve our performance and achieve our ultimate goal of positive patient healing rates and outcomes.”

WCA is an innovative service-based wound care company, providing the necessary tools for a well-equipped wound care program. Transitioning wound care management providers can be a complex undertaking. WCA provides transition specialists to guide hospital executives through the entire process, making it as smooth as possible.

“We welcome anyone interested in learning more about the program or wound care in general, whether patient or provider, to reach out to our highly trained staff,” Mejia said. “We are available to answer questions and/or schedule appointments Monday through Friday, 8 am to 5 pm.”

About Pioneers Memorial Hospital
Pioneers Memorial Hospital (PMH) is a highly respected 107-bed acute care facility accredited by DNV, whose mission is to provide quality healthcare and compassionate service for families of the Imperial Valley. PMH is committed to providing state-of-the-art healthcare and the highest quality community education. PMH is a level 4 trauma center and offers a modern sixteen-bed emergency facility, staffed with board-certified emergency physicians. Within the Phyllis Dillard Family Medical Center is a dual surgery suite for obstetrical and gynecological surgeries. There are fourteen LDRP (Labor and Delivery, Recovery, Postpartum) suites in our Perinatal Department within the Center and we deliver approximately 1,800 babies per year. Pioneers Memorial Healthcare District is proud to be the only ISO 9000:2008 certified hospital in Imperial Valley. ISO 9000:2008 certification is an international signal of our dedication and commitment to protecting our patients’ health and safety while they are with us. To learn more about The Wound Clinic at Pioneers visit or call (760) 351-4848.

Read more:

npwt NEWS: Cytori Therapeutics (CYTX) Preclinical Thermal Injury Study Data Published in JournalBurns

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that preclinical and mechanistic data from its thermal injury study, performed with support from the Biomedical Advanced Research and Development Authority (BARDA), was published in the journalBurns, the official journal of the American Burn Association. The paper, entitled “Uncultured adipose-derived regenerative cells seeded in collagen scaffold improves dermal regeneration, enhancing early vascularization and structural organization following thermal burns” (Foubert P and coll. Published online: June 7, 2015 | DOI: 10.1016/j.burns.2015.05.004), is now available online [] and expands upon data presented earlier this year at the American Burn Association meeting.

Negative pressure wound therapy pump system is one of the best wound care therapy in extracting exudate off the wound for faster healing and infection prevention.

This paper reports that seeding Cytori Cell Therapy™ onto a widely used dermal substitute led to improvement in a number of parameters of healing of full thickness burns. Specifically, histopathological assessment demonstrated that the average depth of tissue within the wound was increased by approximately 2-fold in animals treated with Cytori Cell Therapy. This was associated with an increase in collagen deposition (1.7-fold), blood vessel density (1.5-fold), and mean vessel area (1.8-fold). Immunohistochemical analysis revealed an increase in the number of vessels expressing α-SMA (a marker for mature blood vessels) in animals treated with Cytori’s Cell Therapy. Taken together, these results demonstrate that seeding Cytori Cell Therapy onto this scaffold promotes blood vessel maturation. Finally, the findings showed increased vascularity (1.5-fold) and cellularity (1.45-fold) of the dermal substitute itself.

Kinetix conceptions is the first to enter the the negative pressure wound therapy in partnership with a university that perfected and completed the research on the efficacy of the npwt.

Use of skin substitutes provides an important option for care of patients with larger burns who cannot undergo definitive wound coverage in a single procedure. Such options will be particularly important following a mass casualty event that could overwhelm the capacity of specialist burn care centers. In this context a considerable portion of burn care will likely have to be provided by medical personnel without specialist burn surgery experience.

“The data in this paper present a picture of accelerated maturation and organization of the tissue both within the wound and within the skin substitute,” stated John Fraser, Cytori’s Chief Scientist. “This ability to enhance healing supports a paradigm in which Cytori Cell Therapy is used to improve the quality and rate of wound healing and to reduce scarring when used in combination with a range of temporary and permanent skin substitutes thereby providing a means of improving burn care.”

This research, funded by a contract from the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services, will be included in an Investigational Device Exemption (IDE) package to be submitted to FDA for a proposed clinical trial using Cytori Cell Therapy in thermal burn injury.


While there has been tremendous improvement in survival following severe thermal burn injury, hospitalization time, the development of scarring with pain and restricted range of motion, and other problems at both the injury and skin graft donor site remain significant issues. Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In addition, during a mass casualty event, availability of specialized burn centers for burn injuries may be limited and alternative therapeutic approaches will likely be required. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.

Discovering a new force driving cell contraction during development and organogenesis

Discovering a new force driving cell contraction during development and organogenesis

CRG scientists in Barcelona, Spain describe a new mechanism shaping cells and generating cell contractile forces during development and organogenesis

Center for Genomic Regulation

VIDEO: This video shows the dynamics of dorsal closure in an embryo expressing the caspase marker Apoliner5. At the onset of the process, the GFP fluorescent signal is transferred from the… view more

Credit: Laure Saias, CRG

This news release is available in Spanish.

CRG scientists describe a new mechanism shaping cells and generating cell contractile forces during development and organogenesis.
The new mechanism, which has been published today in the journal Developmental Cell, includes strategies shared with programmed cell death but which have not previously been directly associated with force generation.
Studying developmental processes such as the one presented in the Dev. Cell paper contributes to a better understanding of organ development and maintenance. Also, the specific process of dorsal closure described in this work is one of the most studied ones because of its similarity with wound healing.

Cells and tissues must generate forces to shape organs and for proper development. A team of scientists led by Jérôme Solon at the Centre for Genomic Regulation has just described a new mechanism for the generation of the forces that drive cell movements during development. They were particularly focused on one of the most studied developmental processes: the Drosophila dorsal closure.

Negative Pressure wound therapy pump system is usually used for hard to heal wounds to help extract the exudate out of the wound for faster healing

Dorsal closure is a process by which skin cells on the embryo stretch over a gap to close it. Briefly, accepted mechanism of this process has been that the edges of the gap form a kind of zipper that pulls the skin cells of the embryo together, to shape them and to lead to the next development stage. There are many research groups studying development and some of them focus in particular on dorsal closure because it is genetically and mechanically similar to wound healing in mammals such as ourselves.

“Mechanisms shaping cells and tissues described until now are based on forces generated by the remodelling of the cell cytoskeletal meshwork and structures that pull, push or shrink cells. What we have now described is that cells can also generate forces simply by modulating their volume”, says Jérôme Solon, group leader of the Biomechanics of Morphogenesis group at the CRG in Barcelona.

Halo Mini negative pressure wound therapy pump system is now used to extract exudate and reinforce wound healing with great oxidation.You can also use black foam and white foam dressing when using the halo mini npwt pump system.

Solon and colleagues made a quantitative description of dorsal closure at a tri-dimensional level. They imaged the cells and, together with the physicist Guillaume Salbreux at the Francis Crick Institute in London, built a 3D model to enhance our understanding of what was happening at the single cell level. “Surprisingly, we found that cells were not elongating or changing their shape in the manner that was previously thought, but that the cells were actually changing their volume and shrinking.” When looking at the cells in most of the mechanisms underlying tissue contraction during development, we can see how they are changing their shape, turning flat cells into pear-like cells without an alteration in volume. However, in this case, the researchers observed that cells retain their thickness but decreased their volume, getting smaller.

When cell death is the engine for life

“The most curious thing is that the mechanisms driving these volume changes are the same as those that have been found during programmed cell death or apoptosis. So, it is important for us to highlight the dual role of apoptosis in this particular developmental process. We feel that these mechanisms are likely to play important roles in other morphogenetic processes shaping tissues and organs, such as wound healing and limb or brain development”, concludes Solon.


This research has been supported by the Spanish Ministry of Economy and Competitiveness through the Plan Nacional.


Saias et al. Decrease in Cell Volume Generates Contractile Forces Driving Dorsal Closure, Developmental Cell (2015).

Educational classes for diabetic management

Poughkeepsie, N.Y. – The Vassar Brothers Wound Care and Hyperbaric Medicine Center will begin a monthly education series on diabetes management for patients and caregivers with a lecture and discussion by Dr. Francine Brooks titled “Wound Healing and Diabetes.”

The free lecture is from 5 to 6 p.m. on Tuesday, June 23, in Conference Room B of Vassar Brothers Medical Center, 45 Reade Place, Poughkeepsie.

Equinox Medical is now looking for distributors for their halo mini negative pressure wound therapy pump system. The pump is used for hard to heal wounds such as diabetic foot ulcers and venous ulcer wounds.

“Preventing chronic diseases such as diabetes is a priority for Health Quest and Vassar Brothers Medical Center,” said Charlene Yousey, director of the Vassar Brothers Wound Care Center. “It’s also very important that we continue to educate those who have diabetes how to properly manage it and maintain a good quality of life.”

Brooks is co-medical director of the Vassar Brothers Wound Care and Hyperbaric Medicine Center. She is a physician with Health Quest Medical Practice in the City of Poughkeepsie, who specializes in emergency and internal medicine. She received her medical degree from Albert Einstein College of Medicine in the Bronx. She did her postgraduate work in emergency medicine at Bronx Municipal Hospital Center and in internal medicine at St. Luke’s-Roosevelt Hospital Center in New York City.

NPWT Black wound dressing kits are usually used for this foot ulcers to help extract the exudate out of the wounds.

This series aims to provide education and support for diabetic patients and their family members. It will continue on the fourth Tuesday of every month. Pre-registration is required for all who attend.

Licensed Social Worker and Certified Case Manager Marion Levine, who has worked at Vassar Brothers Medical Center for several years, will also attend each lecture to answer questions and offer support. Attendees will also receive information on proper nutrition and medication.

The schedule for the remainder of 2015 will include topics such as eye health, caregiver support, diabetes and vascular health and podiatry. The speakers are Dr. Daniel Brocks of Hudson Valley Eye Surgeons (July 28), social worker Marion Levine (Aug. 25), Dr. Andreas Spirig of The Vascular Group (Sept. 22), a physician from Seeta Eye Associates (Oct. 27) and Dr. John Zboinski of Rhinebeck Foot Care (Nov. 24). All physicians are on the medical staff of Vassar Brothers Medical Center.

To pre-register to attend one or all of the lectures or for more information, please call 845-431-2445.

Negative Pressure Wound Therapy Market Is

Negative Pressure Wound Therapy Market Is Expected to Reach CAGR of 7.97% amid 2014-2019: Says Report via MarketResearchReports.Biz


Negative weight wound treatment is a method that applies negative weight to an injury to advance injury mending by evacuating the liquid and irresistible materials from the injury. This treatment is useful in treating different sorts of wounds, for example, intense injury and unending injury. Negative weight wound treatment framework comprises of a vacuum pump, a froth or bandage wound dressing, seepage tubing, and a glue film dressing to cover and seal the injuries.

The Global Negative Pressure Wound Therapy business sector to develop at a CAGR of 7.97 percent over the period 2014-2019.

Secured in this Report

The report covers the present situation and the development prospects of the Global Negative Pressure Wound Therapy market for the period 2015-2019. In view of innovation, the business sector can be portioned as takes after: Standard Negative Pressure Wound Therapy and Single-utilization Negative Pressure Wound Therapy.

The Global Negative Pressure Wound Therapy Market 2015-2019, has been arranged in view of a top to bottom business sector investigation with inputs from industry specialists. The report covers the Americas, and the APAC and EMEA locales; it additionally covers the Global Negative Pressure Wound Therapy business scene and its development prospects in the impending years. The report incorporates an exchange of the key merchants working in this business sector.

Download Sample Copy of this Report at

Key Regions




Key Vendors

Active Concepts

Mölnlycke Health Care

Smith & Nephew

Other Prominent Vendors



DeRoyal Industries

Devon Medical Products

Foryou Medical Electronics

Imaginative Therapies





Talley Group

Market Driver

Ascend in Prevalence of Diabetes

For a full, nitty gritty rundown, see our report

Business Challenge

Absence of Awareness

For a full, definite rundown, see our report

Business sector Trend

Ascend being used of Single-utilization Negative Pressure Wound Therapy System

For a full, point by point rundown, see our report

Key Questions Answered in this Report

What will the business size be in 2019 and what will the development rate be?

What are the key business patterns?

What is driving this business?

What are the difficulties to market development?

Who are the key sellers in this business space?

What are the business opportunities and dangers confronted by the key merchants?

What are the qualities and shortcomings of the key sellers?

Scan Blog at

About ( is the most complete gathering of statistical surveying reports, supporting customers’ business sector insight needs with more than 100,000 statistical surveying reports, organization profiles, information books, and territorial business sector benefits in its store. We likewise offer counseling backing for custom statistical surveying needs.Our archive database is overhauled by the hour, which implies that our clients dependably have admittance to new information traversing more than 300 commercial ventures. From Fortune 500 organizations to SMEs, has assembled a veritable notoriety for satisfying the most demanding statistical surveying nee

Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition

Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition

LANGHORNE, Pa., June 1, 2015 (GLOBE NEWSWIRE) — Alliqua BioMedical, Inc. (Nasdaq:ALQA) (“Alliqua” or “the Company”), a provider of advanced wound care products, today announced that it has completed its acquisition of Celleration, Inc. (“Celleration”).

On February 2, 2015, Alliqua announced it has entered into an agreement to purchase Celleration for an initial purchase price of approximately $30.4 million, comprised of both cash and stock. The merger agreement provides for additional contingent payments in stock and cash, under certain circumstances, if stated revenue thresholds are reached over the next two years ending December 31, 2016 or if certain milestones are satisfied in connection with product sales in the U.K.

Celleration is a privately held medical device company, based in Eden Prairie, Minnesota, which is focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds. Celleration’s MIST Therapy System is an FDA 510(k) cleared device that uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process.

“The completion of this acquisition marks another major milestone in our Company’s path towards building a broad and innovative portfolio of advanced wound care technologies,” said David Johnson, Chief Executive Officer of Alliqua. “Celleration’s FDA 501(k) cleared MIST Therapy and UltraMIST™ devices are complementary additions to our portfolio that fit squarely within our acquisition criteria for new technologies. We are also pleased to be expanding the Alliqua team with some highly skilled individuals from Celleration, including nearly twenty sales resources, and we look forward to their contributions in 2015 and beyond.”

Cowen and Company, LLC served as Alliqua’s exclusive financial advisor in connection with this transaction.


Alliqua obtained a Senior Secured Term Loan from Perceptive Advisors in the principal amount of $15.5 million to finance the initial cash purchase price of the acquisition.

Further details of the acquisition and the Senior Secured Term Loan can be found in Alliqua’s Form 10-Q, filed with the SEC on May 14, 2015.

About Alliqua BioMedical, Inc.

Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds.

Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.

In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua’s electron beam production process, located at its 16,500 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua’s hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.

For additional information, please visit To receive future press releases via email, please visit

Equinox Medical, LLC is the fastest growing manufacturer of negative pressure wound therapy black foam dressing in the United States of America. They’ve launched their smallest and reliable Halo mini npwt pump system last year.

About Celleration, Inc.:

Celleration develops and markets a proprietary technology that has been proven to accelerate healing in wounds by delivering therapeutic, low-frequency ultrasound without direct contact of the delivery device to the wound surface. Celleration’s core product, the MIST Therapy System, has been clinically shown to positively impact the wound healing process and to provide clinical and economic benefits to institutions treating nonresponding wounds. MIST therapy has been performed more than 1.2 million times on over 85,000 patients. There are 19 peer-reviewed published articles, including eight Randomized Controlled Trials and one Meta-analysis, documenting the clinical outcomes of MIST.

Legal Notice Regarding Forward-Looking Statements

DermaPure® Saves 18 Year Old’s Leg From Frost Bite

DermaPure® Saves 18 Year Old’s Leg From Frost Bite & is Fe tured on US TV Programme